Shaden Yassin None;
Thomas Khuu None;
Ryan Schmidt None;
Austin Igelman None;
Molly Marra None;
Hillary Schwartz None;
Evan Walker grant P30EY022589, Code R (Recipient);
Aaron Nagiel Lexitas, Eyebiotech, Biogen, Novartis, Atsena, Janssen, Code C (Consultant/Contractor);
Mark Pennesi 4D Molecular Therapeutics, Abbvie, Adverum, AGTC, Aldebaran, Alnylam, Ascidian, Atsena, Astellas, Bayer, Biogen, BlueRock-Opsis, ClarisBio, DTx Therapeutics, Editas, Endogena, Eyevensys, Foundation Fighting Blindness, Intergalactic Therapeutics, IVERIC, Janssen, Mogrify, Nacuity Pharmaceuticals, Novartis, Ocugen, ProQR, Prime Editing, PYC Therapeutics, Rejuvitas, RestoreVision, RegenexBio, Roche, Sanofi, Saliogen, Sparing Vision, TwentyTwenty, Thea, Viewpoint Therapeutics, Vedere, , Code C (Consultant/Contractor), Sanofi, ProQR, Foundation Fighting Blindness, Editas, Biogen, AGTC, , Code F (Financial Support), Atsena, DTx Therapeutics, Nacuity Pharmaceuticals, Ocugen, Vedere, Sparing Vision, Eyevensys, , Code R (Recipient);
Shyamanga Borooah Foundation Fighting Blindness, Nixon Vision Award, Code R (Recipient)